[go: up one dir, main page]

WO1999022005B1 - Heparan sulfate d-glucosaminyl 3-o-sulfotransferases, an uses therefor - Google Patents

Heparan sulfate d-glucosaminyl 3-o-sulfotransferases, an uses therefor

Info

Publication number
WO1999022005B1
WO1999022005B1 PCT/US1998/022597 US9822597W WO9922005B1 WO 1999022005 B1 WO1999022005 B1 WO 1999022005B1 US 9822597 W US9822597 W US 9822597W WO 9922005 B1 WO9922005 B1 WO 9922005B1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
seq
host cell
residues
group
Prior art date
Application number
PCT/US1998/022597
Other languages
French (fr)
Other versions
WO1999022005A2 (en
WO1999022005A3 (en
Inventor
Robert D Rosenberg
Nicholas W Shworak
Jian Liu
Linda M S Fritze
John J Schwartz
Lijuan Zhang
Original Assignee
Massachusetts Inst Technology
Robert D Rosenberg
Nicholas W Shworak
Jian Liu
Linda M S Fritze
John J Schwartz
Lijuan Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, Robert D Rosenberg, Nicholas W Shworak, Jian Liu, Linda M S Fritze, John J Schwartz, Lijuan Zhang filed Critical Massachusetts Inst Technology
Priority to AU11997/99A priority Critical patent/AU1199799A/en
Publication of WO1999022005A2 publication Critical patent/WO1999022005A2/en
Publication of WO1999022005A3 publication Critical patent/WO1999022005A3/en
Publication of WO1999022005B1 publication Critical patent/WO1999022005B1/en
Priority to US09/557,262 priority patent/US6861254B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/13—Transferases (2.) transferring sulfur containing groups (2.8)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Disclosed are novel isolated nucleic acids and substancially pure protein preparations for naturally occurring and synthetic or chimeric heparan sulfate D-glucosaminyl 3-O-sulfo-transferases (3-OSTs). Also disclosed are uses for these genes and proteins, including uses for the modification and sequencing of glycosaminoglycans.

Claims

AMENDED CLAIMS
[received by the International Bureau on 30 August 1999 (30.08.99); original claim 7 amended; remaining claims unchanged (1 page)]
(c) residues 42-109, 313-325, 303-332, or 110-367 of SEQ ID NO: 6; (d) residues 44-147, 351-363, 341-370, or 148-406 of SEQ ID NO: 8; (e) residues 66-132, 336-348, 326-355, or 133-390 of SEQ ID NO: 10; (f) residues 396-408, 386-4150, or 207-456 of SEQ ID NO: 12; (g) residues 240-250, 230-257, 23-291 of SEQ ID NO: 15; (h) a sequence having at least 60% amino acid sequence similarity with at least one of (a)-(g) and encoding a functional fragment having sequence-specific HS binding affinity or 3-O- sulfotransferase activity; and (i) a sequence comprising a chimera of at least two of sequences (a)-(h). 7. An isolated nucleic acid comprising at least 18-20 consecutive nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 , SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, and SEQ ID NO: 11. 8. A host cell transformed with a nucleic acid of any one of claims 1-7, or a descendant thereof. 9. A host cell as in claim 8 wherein said host cell is selected from the group consisting of bacterial cells, yeast cells, and insect cells. 10. A host cell as in claim 8 wherein said host cell is selected from the group consisting of somatic cells, fetal cells, embryonic stem cells, zygotes, gametes, germ line cells, and transgenic animal cells. 11. A host cell as in claim 8 wherein said cell is a mammalian cell. 12. A host cell as in claim 11 wherein said cell is selected from the group consisting of. COS- 7 cells, CHO, murine primary cardiac microvascular endothelial cells (CME), murine mast cell line C57.1, human primary endothelial cells of umbilical vein (HUVEC), F9 embryonal carcinoma cells, rat fat pad endothelial cells (RFPEC), L cells, and cells derived from the transgenic animals of the invention.
13. A substantially pure protein preparation comprising at least a functional fragment of a 3- OST protein. 14. A substantially pure protein preparation as in claim 13 wherein said 3-OST protein is selected from the group consisting of mature murine 3-OST-l and mature human 3-OST-l .
PCT/US1998/022597 1997-10-24 1998-10-23 Heparan sulfate d-glucosaminyl 3-o-sulfotransferases, an uses therefor WO1999022005A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU11997/99A AU1199799A (en) 1997-10-24 1998-10-23 Heparan sulfate d-glucosaminyl 3-(o)-sulfotransferases, an uses therefor
US09/557,262 US6861254B1 (en) 1997-10-24 2000-04-24 Heparan sulfate D-glucosaminyl 3-O-sulfotransferases, and uses therefor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6276297P 1997-10-24 1997-10-24
US60/062,762 1997-10-24
US6543797P 1997-10-31 1997-10-31
US60/065,437 1997-10-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/557,262 Continuation US6861254B1 (en) 1997-10-24 2000-04-24 Heparan sulfate D-glucosaminyl 3-O-sulfotransferases, and uses therefor

Publications (3)

Publication Number Publication Date
WO1999022005A2 WO1999022005A2 (en) 1999-05-06
WO1999022005A3 WO1999022005A3 (en) 1999-10-07
WO1999022005B1 true WO1999022005B1 (en) 1999-11-11

Family

ID=26742665

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/022597 WO1999022005A2 (en) 1997-10-24 1998-10-23 Heparan sulfate d-glucosaminyl 3-o-sulfotransferases, an uses therefor

Country Status (2)

Country Link
AU (1) AU1199799A (en)
WO (1) WO1999022005A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7070700A (en) * 1999-08-25 2001-03-19 Massachusetts Institute Of Technology Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry
US6977248B1 (en) * 1999-08-25 2005-12-20 Massachusetts Institute Of Technology Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry
US6420150B1 (en) * 2000-11-27 2002-07-16 Pe Corporation (Ny) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
GB0111637D0 (en) * 2001-05-12 2001-07-04 Astrazeneca Ab Methods
CA2458182A1 (en) * 2001-08-23 2003-03-06 Sumitomo Chemical Company, Limited Method for assessing cancerous state of mammal-derived specimen
WO2004005475A2 (en) * 2002-07-05 2004-01-15 University Of North Carolina At Chapel Hill Purified and isolated heparan sulfate 3-o-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same
US7166763B2 (en) * 2003-02-10 2007-01-23 Trustees Of Dartmouth College Mouse model of myxomatous valvular disease
EP3911737A1 (en) * 2019-01-15 2021-11-24 Optimvia, LLC Engineered aryl sulfate-dependent enzymes
JP2022540849A (en) * 2019-07-09 2022-09-20 オプティムヴィア、エルエルシー Method for synthesizing anticoagulant polysaccharide
EP4453192A1 (en) * 2021-12-21 2024-10-30 University of Copenhagen Improved heparan sulfate and methods of making the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541095A (en) * 1992-06-16 1996-07-30 University Of Massachusetts Medical Center Glycosaminoglycan specific sulfotransferases
GB2295012B (en) * 1994-10-29 1998-10-07 Cancer Res Campaign Tech Sequence analysis of saccharide material

Also Published As

Publication number Publication date
WO1999022005A2 (en) 1999-05-06
AU1199799A (en) 1999-05-17
WO1999022005A3 (en) 1999-10-07

Similar Documents

Publication Publication Date Title
Rand et al. Cloning and expression of a protective antigen from the cattle tick Boophilus microplus.
Klungland et al. The role of melanocyte-stimulating hormone (MSH) receptor in bovine coat color determination
Scott et al. Structural relationships among genes that control development: sequence homology between the Antennapedia, Ultrabithorax, and fushi tarazu loci of Drosophila.
EP1303536B1 (en) Novel fibroblast growth factor (fgf23) and methods for use
US6268212B1 (en) Tissue specific transgene expression
Steele Jr et al. A mutation in the connexin 50 (Cx50) gene is a candidate for the No2 mouse cataract
Irwin et al. Multiple cDNA sequences and the evolution of bovine stomach lysozyme
JPH01502985A (en) Leukemia inhibitory factor
KR20010031210A (en) NOVEL MODIFIED NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING mRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS
US6103466A (en) Double-muscling in mammals
DE69232544T2 (en) VITAMIN-K-DEPENDENT CARBOXYLASE
WO1999022005B1 (en) Heparan sulfate d-glucosaminyl 3-o-sulfotransferases, an uses therefor
AU7891498A (en) Flower organ-specific gene and its promoter sequence
KR20170058985A (en) Materials and methods for producing animals with short hair
Siracusa et al. The tight skin (Tsk) mutation in the mouse, a model for human fibrotic diseases, is tightly linked to the β2-microglobulin (B2m) gene on chromosome 2
Sangiorgi et al. Analysis of cDNA and genomic clones coding for the proα1 chain of calf Type II collagen
WO1994013794A1 (en) Human thrombospondin-4
NZ291735A (en) Enhanced expression of recombinant protein
US20010007756A1 (en) Cosmetic compositions
Sugahara et al. Characterization of the O-glycosylation sites in the chorionic gonadotropin β subunit in vivo using site-directed mutagenesis and gene transfer
JP2006262875A (en) GENE CONSTRUCTION FOR EXPRESSING PROTEIN IN Avian Oviduct, AND METHOD FOR PRODUCING PROTEIN USING SAME
AU3200195A (en) Ikaros transgenic cells and animals
US6960649B2 (en) Human potassium channel polynucleotides and polypeptides and uses thereof
AU2004201496A1 (en) DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof
JPH08154681A (en) Bovine LIF gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: B1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase in:

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: CA